TLDR
- HCA stock closed at $327.92 on April 25, down 3.95%.
- Q1 2025 EPS rose over 20% to $6.45.
- Emergency room visits increased 4% year-over-year.
- The company completed $6 billion in share repurchases.
- Analysts project 5.4% annual revenue growth through 2028.
HCA Healthcare (NYSE: HCA) reported a robust start to 2025, although shares closed at $327.92 on April 25, slipping 3.95% despite the upbeat earnings. Diluted earnings per share surged over 20% to $6.45, fueled by solid inpatient and emergency room volume growth. Revenue climbed to $18.32 billion, while net income ticked higher to $1.61 billion.
The company highlighted a 2.6% year-over-year rise in inpatient admissions and a 2.8% boost in equivalent admissions. Emergency room visits rose 4%, helping to drive almost a 6% increase in same-facility revenue. Revenue per equivalent admission also grew about 3%.
Operating margins expanded, aided by a 9.3% drop in contract labor costs, and adjusted EBITDA margin improved by 110 basis points.
Expanding Network and Strategic Moves
HCA’s strategic focus on expansion was evident with a 3.3% rise in facilities, now totaling around 2,750, and a 2% increase in inpatient bed capacity. Inpatient occupancy rose to 77% from 75% a year ago.
Capital expenditures reached $991 million during Q1, reflecting continued investment in growth. The company spent $227 million on acquisitions, including Catholic Medical Center and Lehigh Medical Center, while proceeds from asset sales totaled $161 million.
To enhance shareholder value, HCA completed a massive $6 billion share buyback and paid $180 million in dividends. A quarterly dividend of $0.72 per share was announced, reinforcing the company’s focus on returning cash to shareholders.
Positive Trends with a Few Concerns
Despite the strong numbers, outpatient surgical volumes declined slightly, attributed to lower acuity cases and reduced Medicaid and self-pay volumes. Behavioral health volumes also dipped, mainly due to the repurposing of beds for medical-surgical use.
The company continues to monitor uncertainties around federal policy changes and tariffs on supplies, which could pose risks moving forward.
Managed care admissions rose 5.4%, and exchange admissions surged 22.4%, pointing to a favorable payer mix that supports stable cash flows.
Looking Ahead: Growth Potential Remains
Analysts are optimistic about HCA’s future, forecasting 5.4% annual revenue growth and earnings reaching $7 billion by April 2028. At the current price of $327.92, HCA is trading about 12% below the one-year target estimate of $371.34.
Over five years, HCA has delivered a total return of over 216.59%, outpacing the S&P 500’s 94.77% gain during the same period. Recent financial achievements and shareholder-focused initiatives position HCA Healthcare to maintain positive momentum, although investors should weigh Medicaid uncertainties and external risks.
🚨 Our April Stock Picks Are Live!
A new month means new opportunities. Our analysts have just released their top stock picks for April, highlighting companies with strong momentum that rank highly on our KO Score algorithm. We’re also now sharing trade ideas for both long-term and short-term investors, giving you more ways to spot potential opportunities in the market.
Sign up to Knockout Stocks today and get 50% off to unlock the full list and see which stocks made the cut.
Use coupon code Special50 for your exclusive discount!
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
